Related Experiment Videos
[Systematic neonatal screening for Duchenne muscular dystrophy]
Insights
Neonatal screening for Duchenne muscular dystrophy (DMD) via Creatine-Kinase (CK) blood tests can identify affected relatives early. This systematic approach aids genetic counseling and enables timely prenatal diagnosis for preventable cases.
Area of Science:
- Biochemistry and Molecular Biology
- Clinical Genetics
- Neonatal Screening
Context:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder.
- Early diagnosis is crucial for management and genetic counseling.
- Existing diagnostic methods may not capture all at-risk neonates.
Purpose:
- To evaluate a systematic neonatal screening program for Duchenne muscular dystrophy (DMD).
- To assess the efficacy of Creatine-Kinase (CK) activity measurement in neonatal blood spots for early DMD detection.
- To explore the integration of DMD screening into existing newborn screening programs.
Summary:
- A neonatal screening program utilizing Creatine-Kinase (CK) blood level analysis in newborns is proposed for early Duchenne muscular dystrophy (DMD) identification.
- The bioluminescent reaction for CK evaluation is highly specific and accurate, ensuring reliable screening results.
- This method allows for blood sample collection on paper, facilitating centralized laboratory analysis and integration with phenylketonuria screening.
Impact:
- Facilitates early identification of affected relatives, potentially preventing 15% of DMD cases.
- Enhances genetic counseling by providing timely information to families.
- Increases the likelihood of utilizing prenatal diagnostic options, including sex determination and in utero blood sampling.
Abstract:
More than 15% of cases of Duchenne muscular dystrophy (DMD) may be preventable by the neonatal diagnosis of another affected relative. Systematic neonatal screening seems a more efficient way of getting information for genetic counseling. The principle of the test described is the detection of a specific increase of the activity of Creatine-Kinase (CK) in the blood of newborn children with myopathy. Blood may be spotted on paper and posted to a central laboratory. Furthermore this program can be integrated into the systematic screening of phenylketonurie. The specificity and accuracy of the bioluminescent reaction used for the evaluation of CK suggest that this screening reaction is reliable. A systematic neonatal screening program for DMD such as ours in the Rhône-Alpes area (France) will lead to frequent recourse to prenatal diagnosis now possible through sex fetal determination and which would be possible through in utero blood sampling.